AKBA — AKEBIA THERAPEUTICS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About AKEBIA THERAPEUTICS INC (AKBA)
AKEBIA THERAPEUTICS INC (AKBA) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $10M. Across recent filings, tracked investors recorded 5 new positions, 1 increased, 1 reduced, and 0 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in AKBA
How many top investors track AKBA
A small number of top investors own this.
AKBA Ownership Composition
How AKEBIA THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.
- Other100.0%
Tracked investors reporting AKBA
- Ken GriffinMar 31, 2026Citadel AdvisorsShares1.7MValue$2.4M% Portfolio0.00%
- Izzy EnglanderMar 31, 2026Millennium ManagementShares2.4MValue$3.3M% Portfolio0.00%
- Paul Tudor JonesMar 31, 2026Tudor Investment CorpShares10.9KValue$15.2K% Portfolio0.00%
Recent activity
- $17.5KFeb 17, 2026
- $15.2KMay 15, 2026
- $2.7MFeb 17, 2026
- $3.3MMay 15, 2026
- Reduced$2.4M(-65.64%)May 15, 2026
- Increased$8.1M(42.66%)Feb 17, 2026
- New$9.6MNov 14, 2025
Frequently asked questions
- How many institutional investors hold AKBA?
- 3 tracked institutional investors disclosed a position in AKBA (AKEBIA THERAPEUTICS INC) in their most recent 13F filing.
- Who is the largest institutional holder of AKBA?
- Ken Griffin, Citadel Advisors, holds the largest disclosed position in AKBA, valued at $10M.
- Did institutional ownership of AKBA increase or decrease?
- Across recent 13F filings, tracked investors recorded 5 new positions, 1 increased, 1 reduced, and 0 fully exited AKBA.
- Where does this AKBA ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.